Jazz Pharmaceuticals plc (JAZZ) revenue by segment
JAZZNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 2, 2026Score 7/30131% above fair value
$247.77+7.06 (+2.93%)
Close on Nov 18, 2026Market cap $16.08BP/E 80.7Yield –
Doanh thu theo bộ phận của Jazz Pharmaceuticals plc
Theo bộ phận kinh doanh
Theo sản phẩm hoặc dịch vụ
| Doanh thu | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % doanh thu | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product sales, net | $4.02B | $3.82B | $3.74B | $3.64B | $3.08B | $2.35B | $2.14B | $1.87B | $1.60B | $1.48B | 94.2% | +5.3% |
| Total Neuroscience | $2.88B | $2.70B | $2.71B | $2.76B | $2.34B | $1.79B | $1.65B | $1.40B | – | – | 67.5% | +6.7% |
| Xywav | $1.66B | $1.47B | $1.27B | $958.43M | $535.30M | $15.26M | $0 | $0 | – | – | 38.8% | +12.5% |
| Total Oncology | $1.13B | $1.11B | $1.02B | $873.84M | – | – | – | – | – | – | 26.5% | +1.6% |
| Epidiolex/Epidyolex | $1.06B | $972.42M | $845.47M | $736.40M | $463.65M | $0 | $0 | – | – | – | 24.8% | +8.9% |
| Rylaze/Enrylaze | $402.92M | $410.85M | $394.23M | $281.66M | – | – | – | – | – | – | 9.4% | -1.9% |
| Zepzelca | $307.31M | $320.32M | $289.53M | $269.91M | $246.81M | $90.38M | $0 | $0 | – | – | 7.2% | -4.1% |
| Royalties and contract revenues | $245.74M | $247.79M | $97.26M | $17.95M | $15.24M | $16.91M | $26.16M | $21.45M | $17.29M | $10.71M | 5.8% | -0.8% |
| High-sodium oxybate AG royalty revenue | $211.73M | $217.58M | $75.92M | $0 | $0 | – | – | – | – | – | 5.0% | -2.7% |
| Defitelio/defibrotide | $199.39M | $216.57M | $184.00M | $194.29M | $197.93M | $195.84M | $172.94M | $149.45M | $133.65M | $108.95M | 4.7% | -7.9% |
| Vyxeos | $146.71M | $162.60M | $147.50M | $127.98M | $134.06M | $121.11M | $121.41M | $100.84M | $33.79M | $0 | 3.4% | -9.8% |
| Xyrem | $146.03M | $233.82M | $569.73M | $1.02B | $1.27B | $1.74B | $1.64B | $1.40B | $1.19B | $1.11B | 3.4% | -37.5% |
| Modeyso | $48.04M | $0 | $0 | – | – | – | – | – | – | – | 1.1% | – |
| Other royalty and contract revenues | $34.01M | $30.21M | $21.34M | $17.95M | $15.24M | – | – | – | – | – | 0.8% | +12.6% |
| Ziihera | $24.81M | $1.05M | $0 | $0 | – | – | – | – | – | – | 0.6% | +2260.6% |
| Sativex | $16.28M | $18.88M | $19.67M | $16.83M | $12.71M | $0 | $0 | – | – | – | 0.4% | -13.8% |
| Other | $14.17M | $11.47M | $13.85M | $6.64M | $9.80M | $6.84M | $17.55M | $39.59M | $49.92M | $30.90M | 0.3% | +23.5% |
| Oncology | – | – | $1.02B | $873.84M | $733.81M | $554.46M | $471.81M | $425.02M | – | – | – | – |
| Sunosi | – | $0 | $0 | $28.84M | $57.91M | $28.33M | $3.71M | $0 | $0 | – | – | – |
| Erwinaze/Erwinase | – | – | $0 | $0 | $69.38M | $147.14M | $177.47M | $174.74M | $197.34M | $200.68M | – | – |
| Rylaze | – | – | $394.23M | $281.66M | $85.63M | $0 | $0 | – | – | – | – | – |
| Total Oxybate | – | – | – | $1.98B | $1.80B | $1.76B | $1.64B | $1.40B | – | – | – | – |
| Prialt | – | – | – | – | – | – | – | $20.84M | $27.36M | $29.12M | – | – |
| Psychiatry | – | – | – | – | – | – | – | – | – | $17.65M | – | – |
Theo khu vực
| Doanh thu | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % doanh thu | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $3.83B | $3.66B | $3.49B | $3.37B | $2.82B | $2.14B | $1.96B | $1.73B | $1.46B | $1.36B | 89.8% | +4.7% |
| Europe | $341.12M | $312.71M | $269.24M | $239.64M | $230.16M | $175.21M | $150.20M | $125.91M | $125.62M | $108.30M | 8.0% | +9.1% |
| All other | $94.87M | $96.14M | $74.98M | $49.36M | $43.84M | $43.82M | $47.40M | $37.44M | $29.61M | $23.75M | 2.2% | -1.3% |
Lấy từ thuyết minh bộ phận và phân tách doanh thu trong hồ sơ 10-K, 10-Q của Jazz Pharmaceuticals (XBRL). Số quý 4 bằng cả năm tài chính trừ chín tháng đầu. Tên bộ phận giữ theo cách công ty tự đặt và có thể đổi khi công ty tái cấu trúc. Tab KPI hiện các bộ phận này cạnh chỉ số vận hành của Jazz Pharmaceuticals, kèm đầy đủ lịch sử, biểu đồ và liên kết tới từng hồ sơ.
See a number that looks wrong?